Clinical Trial Update: Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating CHOP-R followed by Zevalin and Rituxan in follicular lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CHOP-R regimen
• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: University of Pittsburgh | Conditions: Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED